Donate
Category 3

Management of Glioblastoma Multiforme in a patient treated With Ketogenic Metabolic therapy and Modified standard of Care: a 24-Month Follow-Up:

Ahmed M. A. Elsakka, Mohamed Abdel Bary, Eman Abdelzaher, Mostafa Elnaggar, Miriam Kalamian, Purna Mukherjee and Thomas N. Seyfried
Category 3
09/11/2025

Topics

Introduction

Few advances have been made in overall survival for glioblastoma multiforme (GBM)Few advances have been made in overall survival for glioblastoma multiforme (GBM)in more than 40 years. Here, we report the case of a 38-year-old man who presentedwith chronic headache, nausea, and vomiting accompanied by left partial motor seizuresand upper left limb weakness. Enhanced brain magnetic resonance imagingrevealed a solid cystic lesion in the right partial space suggesting GBM. Serum testingrevealed vitamin D deficiency and elevated levels of insulin and triglycerides. Prior tosubtotal tumor resection and standard of care (SOC), the patient conducted a 72-hwater-only fast. Following the fast, the patient initiated a vitamin/mineral-supplementedketogenic diet (KD) for 21 days that delivered 900 kcal/day.

Read More

Back to Publications

Other Publications of Interest

Category 3

Nontoxic Targeting of Energy Metabolism in Preclinical VM-M3 Experimental Glioblastoma:

Temozolomide (TMZ) is part of the standard of care for treatingIntroduction: Temozolomide (TMZ) is part of the standard of care

Read More
Category 4

Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?

Introduction No major advances have been made in improving overall survival for glioblastoma (GBM) in almost 100 years. The currentNo

Read More
Category 4

Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma:

Introduction Glioblastoma (GBM) is an aggressive primary human brain tumour that has resisted effectiveGlioblastoma (GBM) is an aggressive primary human

Read More
Donate